BioStem Technologies (OTCMKTS:BSEM) Stock Rating Upgraded by Zacks Research

BioStem Technologies (OTCMKTS:BSEM) was upgraded by Zacks Research to a “hold” rating in a report issued on Wednesday,Zacks.com reports.

BioStem Technologies Stock Performance

OTCMKTS BSEM opened at $5.08 on Wednesday. The stock has a 50 day moving average price of $5.65 and a 200-day moving average price of $4.98. BioStem Technologies has a one year low of $3.09 and a one year high of $15.74. The company has a market capitalization of $85.56 million, a P/E ratio of 5.98 and a beta of -0.33.

BioStem Technologies Company Profile

BioStem Technologies, Inc, a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases. The company is also engages in the repackaging and distribution of active pharmaceutical ingredients and other pharmaceutical compounding supplies; and develops and markets nutraceutical products under the Dr.